RXi Pharmaceuticals continues to gain momentum Print E-mail
By M.E.Garza   
Wednesday, 13 October 2010 05:09

Shares of RXi Pharmaceuticals (NASDAQ:RXII) kept pushing higher on Tuesday, finally closing the regular trading session up at $3.21 +0.37 (13.03%) and ticking even higher during after hours trading.

The stock has been picking up volume and it has continued to display very bullish behavior since we reported in September that the company is rumored to be close to a partnership deal with Pfizer.

We continue to be bullish on shares of RXi Pharmaceuticals as our readers have gained well over 20% since they were alerted to the persistent rumors.

Skeptics of the so called "pump" may have a hard time explaining why the company has brought experienced leadership with proven track records in executing successful strategic alliances and M&A transactions if they aren't truly focused in making the rumored partnership a reality sooner than later.

Even we've been wondering why the company has been staffing up as dramatically as management has been saying they have during their most recent presentations.

Why spend that kind of money in this economy unless something good is cooking?

Oh yeah, and call options are way up. Someone thinks this is going much higher.

Here's a look at the chart: http://alturl.com/27xi4

 

Disclosure: Long RXII




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter